Harvard Medical School2d
Creating the World’s First CRISPR Medicine, for Sickle Cell Disease
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
FOX 29 Philadelphia on MSN1d
CHOP doctors named 'Disruptors of the Year' for groundbreaking sickle cell gene therapy
The Philadelphia Citizen is recognizing CHOP doctors Alexis Thompson and Dr. Stephan Grupp with the 'Disruptors of the Year' ...
Hosted on MSN11h
Advocating increased funding for sickle cell research: A call to action
Sickle cell disease is a severe, inherited blood disorder that primarily affects people of African, Mediterranean, Middle Eastern, and Indian descent.Despite its widespread impact, SCD research has ...
Sickle cell disease is a genetic disorder that causes lifelong suffering—here's what you need to know
Right now, approximately 20 billion red blood cells are busy traveling through your blood vessels. They are delivering oxygen ...
WCJB2d
Just Like You: Young girl, mother write children’s book to help others understand Sickle Cell Anemia
Simmie White is taking control of her own story. The six-year-old girl and her mother want others to understand more about ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Health Affairs11d
An Agenda For Sickle Cell Disease Research That Encompasses Lived Experience
As treatment and care continues to evolve, we must ensure that people living with this disease are able to advocate for ...
Bluebird Bio to Be Taken Private by Carlyle and SK Capital Amid Cash Crunch
(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...